TKTamir Kanias

Tamir Kanias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tamir Kanias has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma testosterone heterogeneity reveals genetic and demographic determinants of donor health and red blood cell quality

    by Fang Fang, Nareg Roubinian, Xutao Deng, Cassie Kemmler, Jost Klawitter, Jelena Klawitter, Touraj Shokati, Uwe Christians, Grier P. Page, Tamir Kanias

    Testosterone is a key determinant of red blood cell (RBC) biology and susceptibility to hemolysis; however, its contribution to donor-dependent variation in RBC quality and transfusion effectiveness remains unclear. Using data from 2,357 male participants in the NHLBI REDS-III RBC-Omics study, we quantified plasma total testosterone, free testosterone (bioavailable form), and androstenedione and evaluated their associations with donor characteristics, RBC hemolysis, and recipient post-transfusion hemoglobin increments, a clinical measure of RBC transfusion effectiveness. Subphysiological testosterone concentrations were common (~35%) and independently associated with increased storage and osmotic hemolysis. Frequent blood donations were independently associated with lower circulating free testosterone concentrations, even after adjustment for demographic and hematologic factors. Genome-wide association analyses identified loci associated with circulating testosterone, including regions near SHBG , TNFSF12 , and the long noncoding RNA BALR6 . Several testosterone variants were associated with RBC transfusion effectiveness. Specifically, variants associated with lower testosterone (e.g., TNFSF12 ) corresponded to higher post-transfusion hemoglobin increments (+9%), whereas BALR6 variants associated with higher testosterone were linked to reduced hemoglobin increments (–40%). In contrast, androstenedione-associated variants were not related to hemolysis or transfusion outcomes. Together, these findings demonstrate that genetic and physiologic variation in testosterone contributes to inter-individual variability in RBC quality and transfusion effectiveness.

  • Open Access

    Donor genetics and storage conditions influence mitochondrial DNA and extracellular vesicle levels in RBC units

    by Xutao Deng, Clara Di Germanio, Erika G. Marques de Menezes, Pamela Milani, Mars Stone, Heather Tanner, Sonia Coco Bakkour, Daniel M. Chafets, Sarah E. Reese, Nareg H. Roubinian, et al.

    Mitochondrial DNA (mtDNA) shares characteristics with bacterial DNA and activates immune cells via TLR9. Extracellular vesicles (EVs) and mtDNA have been found in blood products and can activate immune cells; we sought to characterize their evolution in stored blood products. From a previous study of hemolysis in 13,403 blood donors, a second blood unit was drawn from 651 donors and sampled at days 10, 21, and 42. EV counts and RBC-EVs increased with storage time, and EV levels were higher in males and in RBC units processed in AS-1 compared with AS-3. mtDNA levels were higher in females and RBC units processed in AS-3. EV populations and mtDNA levels were highly correlated within donors for 98 donations obtained 2–12 months apart. Quantitative trait locus analysis revealed several genetic associations, most notably linking mtDNA levels with polymorphisms in ANKLE1 , which encodes an erythroid-specific protein that preferentially cleaves mtDNA. These data suggest that donor-intrinsic factors may influence mtDNA and EV levels found in RBC units. This finding lends impetus to determining if genetic or environmental factors control levels of these immune mediators in blood donors.


  • Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion

    by Tamir Kanias, Gemlyn George, Joseph Sekiya, Kathleen Kelly, Crystal Stanley, Deborah Lee, Jeffrey Finlon, Maria Rahman, Timothy Gehris, Dylan Bowen, et al.

    Background: Red blood cell (RBC) biotinylation has increasingly become the preferred method for quantifying RBC post‐transfusion recovery (PTR). This study evaluated the feasibility of transfusing autologous RBCs labeled with biotin (BioRBCs) 48 h prior to transfusion. The rationale was to facilitate the distribution of BioRBC products from manufacturing sites to remote clinical sites.Study Design: Leukocyte‐reduced RBC units from 12 healthy individuals were stored at 1–6°C for 42 days and biotinylated with two biotin densities (3 and 15 μg/mL) 48 and 4 h prior to transfusion. Each individual was transfused with 10 mL of each BioRBC preparation, after which BioRBC 20 h PTR and long‐term survival (30 and 90 days) were determined by flow cytometric analyses. Additional quality measurements included phosphatidylserine (PS) exposure on BioRBCs and in vitro metrics of hemolysis.Results: RBC transfusion 48 h after biotinylation was not associated with altered BioRBC 20 h PTR or 30 and 90 day survival as compared with RBC transfusion 4 h after biotinylation (e.g., PTR 20 h: 85.7% ± 8.4% vs. 87.5% ± 7.3%; 48 and 4 h, respectively, p > .05). Similarly, no significant differences between the BioRBC groups were observed in BioRBC PS exposure at all time points. BioRBC long‐term survival, but not 20 h PTR, was negatively associated with donor hemoglobin (Pearson r = −0.71, p = .001) and osmotic hemolysis (r = −0.783, p = .003). None of the participants developed antibodies against BioRBCs during the trial.Conclusions: RBC biotinylation 48 h prior to transfusion does not compromise the quality and safety of BioRBC products. BioRBC long‐term survival can be used to identify donor characteristics that influence RBC lifespan in the circulation.


  • Platelet storage in small bags as a model of platelet function in full‐sized containers

    by Kathleen Kelly, Tamir Kanias, Caroline Leite, Crystal Stanley, Larry J. Dumont

    Background: Evaluation of additive solutions, storage containers, new collection and storage methods, and other potential modifications is resource intensive, resulting in diversion of platelets away from blood bank inventories and significant time to complete study recruitments. Our goal was to evaluate the feasibility of a small bag for the study of platelet storage, and, by using a standardized respirometry test, separate daily metabolic capacity from observations made in the dynamic storage environment of changing pH, fuels, and end products.Methods: Single‐donor apheresis platelets collected in 100% plasma had small volumes removed to meet secondary processing requirements. Small volumes (23 ± 1.4 mL) were placed in 50‐mL bags constructed of platelet storage material, stored 7 days, and assessed with a panel of in vitro assays. Platelet bioenergetics (oxygen consumption and acid production rates) were measured with a respirometer.Results: The patterns of platelet pH decline, activation, and potency by thrombin generation were consistent with historical reports. Lactate production rates (54.1 ± 11.3 μmol/1012plt/h) were significantly correlated with pH decrease, increased activation, and thrombin generation potency by Day 7. Respirometry revealed a reduction of the glycolytic capacity and accumulating damage to the oxidative system for ATP production over storage.Discussion: Small bags present a storage profile of metabolic changes and activation consistent with historical data for full bag storage. Therefore, this system has promise to provide a platform for scaling experiments of platelet storage in a manner that maximizes platelets collected in research settings and does not compromise availability for patient treatment as exercised in this study.


  • Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy

    by Alisha Chitrakar, Scott‐Wesley M. Bean, Tamir Kanias, Kimberly A. Thomas

    Background: Critical shortages in the national blood supply have led to a re‐evaluation of previously overlooked donor sources for blood products. As a part of that effort, red blood cells collected from therapeutic phlebotomy of donors on testosterone replacement therapy (TRT) have been conditionally approved for transfusion. However, platelets from TRT donors are not currently approved for use due to limited data on effects of supraphysiologic testosterone on recipient safety and platelet function. The objective of this study was to provide a comprehensive profile of phenotype and function in platelets from TRT and control donors.Study Design and Methods: Platelets in plasma were collected from TRT and control donors (N = 10 per group; age‐ and sex‐matched) and stored at room temperature for 7 days. On storage Day 1 (D1) and Day 7 (D7), platelet products were analyzed for platelet count, metabolic parameters (i.e., glucose, lactate, mitochondrial function), surface receptor expression, aggregation, thrombin generation, and thrombus formation under physiological flow conditions.Results: TRT donor platelets were not significantly different than control donor platelets in terms of count, surface phenotype, metabolic function, ability to aggregate, thrombin generation, or ability to form occlusive thrombus under arterial flow regimes. Both groups were similar to each other by D7, but had significantly lost hemostatic function compared to D1.Discussion: Platelets derived from donors undergoing TRT have similar phenotypic and functional profiles compared to those derived from control donors. This suggests that therapeutic phlebotomy of TRT donors may provide a useful source for platelet products.


  • Testosterone supplementation increases red blood cell susceptibility to oxidative stress, decreases membrane deformability, and decreases survival after cold storage and transfusion

    by Johnson Tran, Rachael P. Jackman, Marcus O. Muench, Kelsey Hazegh, Scott‐Wesley Bean, Kimberly A. Thomas, Fang Fang, Grier Page, Kim O'COnnor, Nareg H. Roubinian, et al.

    Background: Blood collection from donors on testosterone therapy (TT) is restricted to red blood cell (RBC) concentrates to avoid patient exposure to supraphysiological testosterone (T). The objective of this study was to identify TT‐related changes in RBC characteristics relevant to transfusion effectiveness in patients.Study Design: This was a two‐part study with cohorts of patients and blood donors on TT. In part 1, we conducted longitudinal evaluation of RBCs collected before and at three time points after initiation of T. RBC assays included storage and oxidative hemolysis, membrane deformability (elongation index), and oximetry. In part 2, we evaluated the fate of transfused RBCs from TT donors in immunodeficient mice and by retrospective analyses of NIH's vein‐to‐vein databases.Results: TT increased oxidative hemolysis (1.45‐fold change) and decreased RBC membrane deformability. Plasma free testosterone was positively correlated with oxidative hemolysis (r = .552) and negatively correlated with the elongation index (r = −.472). Stored and gamma‐irradiated RBCs from TT donors had lower posttransfusion recovery in mice compared to controls (41.6 ± 12 vs. 55.3 ± 20.5%). Recipients of RBCs from male donors taking T had 25% lower hemoglobin increments compared to recipients of RBCs from non‐TT male donors, and had increased incidence (OR, 1.80) of requiring additional RBC transfusions within 48 h of the index transfusion event.Conclusions: TT is associated with altered RBC characteristics and transfusion effectiveness. These results suggest that clinical utilization of TT RBCs may be less effective in recipients who benefit from longer RBC survival, such as chronically transfused patients.


  • Open Access

    Estimated median density identifies donor age and sex differences in red blood cell biological age

    by Olga Mykhailova, Mackenzie Brandon‐Coatham, Kiarra Durand, Carly Olafson, April Xu, Qi‐Long Yi, Tamir Kanias, Jason P. Acker

    Background: Donors possess heterogeneous red cell concentrates (RCCs) in terms of the biological age of their red blood cells (RBCs) as a direct result of various donor‐dependent factors influencing rates of erythropoiesis. This study aimed to estimate the median biological age of RBCs in RCCs based on donor age and sex to investigate inherent differences in blood products' biological ages over hypothermic storage using estimated median densities (EMDs).Study Design: Sixty RCCs were collected from four donor groups; male and female teenagers (17–19 years old) and seniors (75+ years old). A Percoll density‐based separation approach was used to quantify the EMDs indicative of biological age. EMD and mean corpuscular hemoglobin (MCHC) were compared by correlation analyses.Results: Differences in the median biological age of RCC units were observed with male donors having significantly higher EMDs compared to females (p < .001). Teen male donors possessed the highest EMDs with significantly elevated levels of biologically aged RBCs compared to both female donor groups, regardless of storage duration (p < .05). Throughout most of the 42‐day storage period, senior donors, particularly senior females, demonstrated the strongest correlation between EMD and MCHC (R2 > 0.5).Conclusions: This study provides further evidence that there are inherent differences between the biological age profiles of RBCs between blood donors of different sex and age. Our findings further highlight that biological age may contribute to RBC quality during storage and that donor characteristics need to be considered when evaluating transfusion safety and efficacy.


  • Open Access

    Functional effects of an African glucose‐6‐phosphate dehydrogenase (G6PD) polymorphism (Val68Met) on red blood cell hemolytic propensity and post‐transfusion recovery

    by Ling Wang, Elizabeth R. Rochon, Sebastien Gingras, Benjamin E. Zuchelkowski, Derek J. Sinchar, Elimira Alipour, Julie A. Reisz, Minying Yang, Grier P. Page, Tamir Kanias, et al.

    Background: Donor genetic variation is associated with red blood cell (RBC) storage integrity and post‐transfusion recovery. Our previous large‐scale genome‐wide association study demonstrated that the African G6PD deficient A‐ variant (rs1050828, Val68Met) is associated with higher oxidative hemolysis after cold storage. Despite a high prevalence of X‐linked G6PD mutation in African American population (>10%), blood donors are not routinely screened for G6PD status and its importance in transfusion medicine is relatively understudied.Study Design and Methods: To further evaluate the functional effects of the G6PD A‐ mutation, we created a novel mouse model carrying this genetic variant using CRISPR‐Cas9. We hypothesize that this humanized G6PD A‐ variant is associated with reduced G6PD activity with a consequent effect on RBC hemolytic propensity and post‐transfusion recovery.Results: G6PD A‐ RBCs had reduced G6PD protein with ~5% residual enzymatic activity. Significantly increased in vitro hemolysis induced by oxidative stressors was observed in fresh and stored G6PD A‐ RBCs, along with a lower GSH:GSSG ratio. However, no differences were observed in storage hemolysis, osmotic fragility, mechanical fragility, reticulocytes, and post‐transfusion recovery. Interestingly, a 14% reduction of 24‐h survival following irradiation was observed in G6PD A‐ RBCs compared to WT RBCs. Metabolomic assessment of stored G6PD A‐ RBCs revealed an impaired pentose phosphate pathway (PPP) with increased glycolytic flux, decreasing cellular antioxidant capacity.Discussion: This novel mouse model of the common G6PD A‐ variant has impaired antioxidant capacity like humans and low G6PD activity may reduce survival of transfused RBCs when irradiation is performed.


  • Quality assessment of red blood cell concentrates from blood donors at the extremes of the age spectrum: The BEST collaborative study

    by Marc Cloutier, Fabrice Cognasse, Ana Paula Hitomi Yokoyama, Kelsey Hazegh, Olga Mykhailova, Mackenzie Brandon‐Coatham, Hind Hamzeh‐Cognasse, Jose Mauro Kutner, Jason P. Acker, Tamir Kanias, et al.

    Background: Blood donors at the extremes of the age spectrum (16–19 years vs. ≥75 years) are characterized by increased risks of iron deficiency and anemia, and are often underrepresented in studies evaluating the effects of donor characteristics on red blood cells (RBC) transfusion effectiveness. The aim of this study was to conduct quality assessments of RBC concentrates from these unique age groups.Study design: We characterized 150 leukocyte‐reduced (LR)‐RBCs units from 75 teenage donors, who were matched by sex, and ethnicity with 75 older donors. LR‐RBC units were manufactured at three large blood collection centers in the USA and Canada. Quality assessments included storage hemolysis, osmotic hemolysis, oxidative hemolysis, osmotic gradient ektacytometry, hematological indices, and RBC bioactivity.Results: RBC concentrates from teenage donors had smaller (9%) mean corpuscular volume and higher (5%) RBC concentration compared with older donors counterparts. Stored RBCs from teenage donors exhibited increased susceptibility to oxidative hemolysis (>2‐fold) compared with RBCs from older donors. This was observed at all testing centers independent of sex, storage duration, or the type of additive solution. RBCs from teenage male donors had increased cytoplasmatic viscosity and lower hydration compared with older donor RBCs. Evaluations of RBC supernatant bioactivity suggested that donor age was not associated with altered expression of inflammatory markers (CD31, CD54, and IL‐6) on endothelial cells.Conclusions: The reported findings are likely intrinsic to RBCs and reflect age‐specific changes in RBC antioxidant capacity and physical characteristics that may impact RBC survival during cold storage and after transfusion.